TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in Morrisville, North Carolina and currently employs 399 full-time employees. The firm is focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates are Ublituximab IV (anti-CD20 mAb), Ublituximab Subcutaneous (anti-CD20 mAb), Azer-cel, TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. The company also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition, and/or investment opportunities.
Mr. Michael Weiss is the Chairman of the Board of TG Therapeutics Inc, joining the firm since 2011.
What is the price performance of TGTX stock?
The current price of TGTX is $32.14, it has increased 6.37% in the last trading day.
What are the primary business themes or industries for TG Therapeutics Inc?
TG Therapeutics Inc belongs to Biotechnology industry and the sector is Health Care
What is TG Therapeutics Inc market cap?
TG Therapeutics Inc's current market cap is $5.1B
Is TG Therapeutics Inc a buy, sell, or hold?
According to wall street analysts, 9 analysts have made analyst ratings for TG Therapeutics Inc, including 3 strong buy, 9 buy, 2 hold, 1 sell, and 3 strong sell